Professor Liang Aibin: Breaking Through Relapse and Resistance—Advancing Innovation in Dual-Target CAR-T Therapy | 2025 International Conference on Cell and Immunotherapy

Professor Liang Aibin: Breaking Through Relapse and Resistance—Advancing Innovation in Dual-Target CAR-T Therapy | 2025 International Conference on Cell and Immunotherapy

2026.01.08
To promote innovation in the fields of cell therapy and immunotherapy in China, facilitate in-depth discussion of key scientific challenges, and share the latest clinical research advances from a global perspective, the 2025 International Conference on Cell and Immunotherapy (CTI 2025) was held in Hangzhou, China, from November 13–16, 2025. The meeting was jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Immunology Society, and the Zhejiang Anti-Cancer Association, and co-hosted by The First Affiliated Hospital, Zhejiang University School of Medicine and Liangzhu Laboratory.
Voice of China at ASH | Professor Chen Wenming: Bispecific Antibodies and Other Innovative Therapies Advance the Treatment of RRMM, While Mass Spectrometry Optimizes Response Assessment

Voice of China at ASH | Professor Chen Wenming: Bispecific Antibodies and Other Innovative Therapies Advance the Treatment of RRMM, While Mass Spectrometry Optimizes Response Assessment

2026.01.08
Relapsed/refractory multiple myeloma (RRMM) remains a major clinical challenge due to treatment resistance and poor prognosis, underscoring the urgent need for novel drugs and innovative therapeutic strategies. At the 2025 Annual Meeting of the American Society of Hematology (ASH), Professor Chen Wenming and his team from Beijing Chaoyang Hospital, Capital Medical University presented multiple innovative studies involving bispecific antibodies, the novel agent Eprenetapopt-like TRAIL agonist (Epnamin), and the application of mass spectrometry in minimal residual disease (MRD) monitoring.
Global Perspectives at ASH |Professor Othman Al-Sawaf: The CLL17 Trial Redefines the Treatment Paradigm—Fixed-Duration Therapy Is Non-Inferior to Continuous Treatment

Global Perspectives at ASH |Professor Othman Al-Sawaf: The CLL17 Trial Redefines the Treatment Paradigm—Fixed-Duration Therapy Is Non-Inferior to Continuous Treatment

2026.01.08
The widespread adoption of targeted therapies has significantly improved long-term outcomes for patients with chronic lymphocytic leukemia (CLL). However, a critical question has remained unanswered: Is fixed-duration therapy as effective as continuous treatment? Until now, no prospective head-to-head evidence had directly compared these two strategies.
2026 CASH Major Preview: Global Hematology Leaders Convene — Internati onal Forum Agenda Revealed

2026 CASH Major Preview: Global Hematology Leaders Convene — Internati onal Forum Agenda Revealed

2026.01.06
Organized by Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences, the 6th Annual Meeting of Chinese Alliance for Society of Hematology (CASH) will be held on Jan. 9-11, 2026, in Tianjin, China. Since its inaugural session in 2021, CASH has become one of the most influential academic events in the field of hematology. Looking back at the previous five sessions, the conference has invited top experts and scholars from both China and abroad, attracting millions of online and onsite participants. It has focused on national strategies, exchanged the latest research findings, discussed trends in the development of the discipline, and helped integrate Chinese hematology with the international community, playing an irreplaceable role in the implementation of the Healthy China strategy.
SABCS Expert Commentary | Professor Jin Feng: Precision Immunotherapy Adds New Evidence in Early Triple-Negative Breast Cancer—Gene Expression–Based Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

SABCS Expert Commentary | Professor Jin Feng: Precision Immunotherapy Adds New Evidence in Early Triple-Negative Breast Cancer—Gene Expression–Based Subtyping Predicts Response to Neoadjuvant Immunochemotherapy

2026.01.04
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study entitled “Gene Expression–based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. This study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early-stage triple-negative breast cancer (TNBC), highlighting the predictive value of tumor-infiltrating lymphocytes (TILs) and TNBC molecular subtypes. Oncology Frontier invited Professor Jin Feng and his colleagues Professor Yu Xinmiao and Professor Zheng Ang from the First Hospital of China Medical University to introduce and comment on the study in detail, offering important evidence and clinical insights for precision immunotherapy in TNBC.